Edition:
United States

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

9.02CAD
4:00pm EDT
Change (% chg)

$-0.02 (-0.22%)
Prev Close
$9.04
Open
$9.08
Day's High
$9.17
Day's Low
$8.97
Volume
68,151
Avg. Vol
202,193
52-wk High
$14.75
52-wk Low
$4.96

Chart for

About

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $670.76
Shares Outstanding(Mil.): 76.66
Dividend: --
Yield (%): --

Financials

  TH.TO Industry Sector
P/E (TTM): -- 28.12 30.20
EPS (TTM): -0.16 -- --
ROI: -26.29 13.07 12.77
ROE: -28.88 15.04 14.92

BRIEF-Theratechnologies Says Reached Pricing Agreement With ADAP Crisis Task Force

* THERATECHNOLOGIES INC - REACHED A PRICING AGREEMENT WITH AIDS DRUG ASSISTANCE PROGRAM CRISIS TASK FORCE Source text for Eikon: Further company coverage:

May 23 2018

BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA

* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)

May 01 2018

BRIEF-Theratechnologies To Seek Regulatory Approval Of Trogarzo In Europe

* THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE

Apr 24 2018

BRIEF-Theratechnologies Reports Q1 Loss Per Share C$0.04

* THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018

Apr 05 2018

BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection

* THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1 Source text for Eikon: Further company coverage:

Mar 06 2018

Earnings vs. Estimates